New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature

Autoimmunity Reviews

Volumn 15, Issue 6, 2016, Pages 529-538

  Roccatello, D ^a,b   Sciascia, S ^a   Di Simone, D ^a   Solfietti, L ^a   Naretto, C ^a   Fenoglio, R ^b   Baldovino, S ^a   Menegatti, E ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b S GIOVANNI BOSCO HOSPITAL   (Italy)

Author keywords

IL 35; Innovative treatment of nephrotic syndrome; Membranous nephropathy; Rituximab; T lymphocytes; Therapy of membranous nephropathy; Treg

Indexed keywords

CREATININE; INTERLEUKIN 35; PHOSPHOLIPASE A2 RECEPTOR; RITUXIMAB; ANTINEOPLASTIC AGENT;

ADULT; AGED; B LYMPHOCYTE; CAUCASIAN; CLINICAL ARTICLE; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HOMEOSTASIS; HUMAN; HUMAN TISSUE; HUMORAL IMMUNE DEFICIENCY; IMMUNE RESPONSE; MALE; MEDICAL HISTORY; MEMBRANOUS GLOMERULONEPHRITIS; MULTIPLE CYCLE TREATMENT; PROSPECTIVE STUDY; PROTEINURIA; REGULATORY T LYMPHOCYTE; REMISSION; REVIEW; TREATMENT DURATION; GLOMERULONEPHRITIS, MEMBRANOUS; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RITUXIMAB; TREATMENT OUTCOME;

EID: 84959882234     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.02.014     Document Type: Review

References (73)

1. Medawar W., Green A., Campbell E., Carmody M., Donohoe J., Doyle G., et al. Clinical and histopathologic findings in adults with the nephrotic syndrome. Ir J Med Sci 1990, 159:137-140.
2. Radice A., Trezzi B., Maggiore U., Pregnolato F., Stellato T., Napodano P., et al. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmun Rev 2016, 15:146-154. 10.1016/j.autrev.2015.10.004.
3. Schlumberger W., Hornig N., Lange S., Probst C., Komorowski L., Fechner K., et al. Differential diagnosis of membranous nephropathy with autoantibodies to phospholipase A2 receptor 1. Autoimmun Rev 2014, 13:108-113. 10.1016/j.autrev.2013.09.005.
4. Pani A. Standard immunosuppressive therapy of immune-mediated glomerular diseases. Autoimmun Rev 2013, 12:848-853. 10.1016/j.autrev.2012.11.012.
5. Kattah A.G., Fervenza F.C. Rituximab: emerging treatment strategies of immune-mediated glomerular disease. Expert Rev Clin Immunol 2012, 8:413-421. 10.1586/eci.12.26.
6. Ruggenenti P., Chiurchiu C., Brusegan V., Abbate M., Perna A., Filippi C., et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003, 14:1851-1857.
7. Cattran D.C. Membranous nephropathy: quo vadis?. Kidney Int 2002, 61:349-350. 10.1046/j.1523-1755.2002.00125.x.
8. Fervenza F.C., Sethi S. Glomerular disease in 2014: advances in basic science and translational medicine. Nat Rev Nephrol 2015, 11:67-68. 10.1038/nrneph.2014.248.
9. Fervenza F.C., Sethi S., Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol 2008, 3:905-919. 10.2215/CJN.04321007.
10. Polanco N., Gutiérrez E., Covarsí A., Ariza F., Carreño A., Vigil A., et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010, 21:697-704. 10.1681/ASN.2009080861.
11. Debiec H., Guigonis V., Mougenot B., Decobert F., Haymann J.-P., Bensman A., et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002, 346:2053-2060. 10.1056/NEJMoa012895.
12. Segelmark M., Hellmark T. Autoimmune kidney diseases. Autoimmun Rev 2010, 9:A366-A371. 10.1016/j.autrev.2009.11.007.
13. Beck L.H., Bonegio R.G.B., Lambeau G., Beck D.M., Powell D.W., Cummins T.D., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009, 361:11-21. 10.1056/NEJMoa0810457.
14. Sakkas L.I., Bogdanos D.P. Systemic sclerosis: new evidence re-enforces the role of B cells. Autoimmun Rev 2016, 15:155-161. 10.1016/j.autrev.2015.10.005.
15. Roccatello D., Sciascia S., Baldovino S., Rossi D., Alpa M., Naretto C., et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-clinical response compared to literature and immunological re-assessment. Autoimmun Rev 2015, 10.1016/j.autrev.2015.07.017.
16. Giuggioli D., Lumetti F., Colaci M., Fallahi P., Antonelli A., Ferri C. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev 2015, 14:1072-1078. 10.1016/j.autrev.2015.07.008.
17. Dumoitier N., Terrier B., London J., Lofek S., Mouthon L. Implication of B lymphocytes in the pathogenesis of ANCA-associated vasculitides. Autoimmun Rev 2015, 14:996-1004. 10.1016/j.autrev.2015.06.008.
18. Visentini M., Tinelli C., Colantuono S., Monti M., Ludovisi S., Gragnani L., et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic review. Autoimmun Rev 2015, 14:889-896. 10.1016/j.autrev.2015.05.013.
19. Greco A., De Virgilio A., Rizzo M.I., Gallo A., Magliulo G., Fusconi M., et al. Microscopic polyangiitis: advances in diagnostic and therapeutic approaches. Autoimmun Rev 2015, 14:837-844. 10.1016/j.autrev.2015.05.005.
20. Kamal A., Khamashta M. The efficacy of novel B cell biologics as the future of SLE treatment: a review. Autoimmun Rev 2014, 13:1094-1101. 10.1016/j.autrev.2014.08.020.
21. Remuzzi G., Chiurchiu C., Abbate M., Brusegan V., Bontempelli M., Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet Lond Engl 2002, 360:923-924. 10.1016/S0140-6736(02)11042-7.
22. Bomback A.S., Derebail V.K., McGregor J.G., Kshirsagar A.V., Falk R.J., Nachman P.H. Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 2009, 4:734-744. 10.2215/CJN.05231008.
23. Cravedi P., Sghirlanzoni M.C., Marasà M., Salerno A., Remuzzi G., Ruggenenti P. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol 2011, 33:461-468. 10.1159/000327611.
24. Segarra A., Praga M., Ramos N., Polanco N., Cargol I., Gutierrez-Solis E., et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 2009, 4:1083-1088. 10.2215/CJN.06041108.
25. Ruggenenti P., Cravedi P., Chianca A., Perna A., Ruggiero B., Gaspari F., et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012, 23:1416-1425. 10.1681/ASN.2012020181.
26. Glassock R.J. Human idiopathic membranous nephropathy-a mystery solved?. N Engl J Med 2009, 361:81-83. 10.1056/NEJMe0903343.
27. Guo L., Kapur R., Aslam R., Speck E.R., Zufferey A., Zhao Y., et al. CD20+ B cell depletion therapy suppresses murine CD8+ T cell-mediated immune thrombocytopenia (ITP). Blood 2015, 10.1182/blood-2015-06-655126.
28. Cattran D.C., Pei Y., Greenwood C. Predicting progression in membranous glomerulonephritis. Nephrol Dial Transplant 1992, 7(Suppl. 1):48-52.
29. Cattran D.C., Pei Y., Greenwood C.M., Ponticelli C., Passerini P., Honkanen E. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997, 51:901-907.
30. Bazzi C., Petrini C., Rizza V., Arrigo G., Beltrame A., Pisano L., et al. Urinary excretion of IgG and alpha(1)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy. Am J Kidney Dis 2001, 38:240-248.
31. Fervenza F.C., Abraham R.S., Erickson S.B., Irazabal M.V., Eirin A., Specks U., et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2010, 5:2188-2198. 10.2215/CJN.05080610.
32. Irazabal M.V., Eirin A., Lieske J., Beck L.H., Sethi S., Borland T.M., et al. Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. Nephrol Dial Transplant 2013, 28:137-146. 10.1093/ndt/gfs379.
33. Beck L.H., Fervenza F.C., Beck D.M., Bonegio R.G.B., Malik F.A., Erickson S.B., et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011, 22:1543-1550. 10.1681/ASN.2010111125.
34. Hoxha E., Harendza S., Pinnschmidt H., Panzer U., Stahl R.A.K. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol 2014, 9:1883-1890. 10.2215/CJN.03850414.
35. Hofstra J.M., Wetzels J.F. Anti-PLA[U+2082]R antibodies in membranous nephropathy: ready for routine clinical practice?. Neth J Med 2012, 70:109-113.
36. Segarra-Medrano A., Jatem-Escalante E., Quiles-Pérez M.T., Salcedo M.T., Arbós-Via M.A., Ostos H., et al. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy. Nefrol Publicación Of La Soc Española Nefrol 2014, 34:353-359. 10.3265/Nefrologia.pre2013.Dec.12291.
37. Ruggenenti P., Debiec H., Ruggiero B., Chianca A., Pellé T., Gaspari F., et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 2015, 26:2545-2558. 10.1681/ASN.2014070640.
38. Cravedi P., Ruggenenti P., Sghirlanzoni M.C., Remuzzi G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007, 2:932-937. 10.2215/CJN.01180307.
39. Kattah A.G., Fervenza F.C., Roccatello D. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev 2013, 12:854-859. 10.1016/j.autrev.2012.09.002.
40. Cattran D.C., Appel G.B., Hebert L.A., Hunsicker L.G., Pohl M.A., Hoy W.E., et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001, 59:1484-1490. 10.1046/j.1523-1755.2001.0590041484.x.
41. Choi J., Leung P.S.C., Bowlus C., Gershwin M.E. IL-35 and autoimmunity: a comprehensive perspective. Clin Rev Allergy Immunol 2015, 49:327-332. 10.1007/s12016-015-8468-9.
42. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569. 10.1038/nature06306.
43. Shen P., Roch T., Lampropoulou V., O'Connor R.A., Stervbo U., Hilgenberg E., et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014, 507:366-370. 10.1038/nature12979.
44. Polanco N., Gutiérrez E., Rivera F., Castellanos I., Baltar J., Lorenzo D., et al. Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment. Nephrol Dial Transplant 2012, 27:231-234. 10.1093/ndt/gfr285.
45. Glassock R.J. Diagnosis and natural course of membranous nephropathy. Semin Nephrol 2003, 23:324-332.
46. Ohtani H., Wakui H., Komatsuda A., Okuyama S., Masai R., Maki N., et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant 2004, 19:574-579.
47. Glassock R.J. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis 2010, 56:157-167. 10.1053/j.ajkd.2010.01.008.
48. Ponticelli C. What is the role of rituximab in idiopathic membranous nephropathy?. Expert Rev Clin Immunol 2013, 9:13-16. 10.1586/eci.12.89.
49. Cravedi P., Remuzzi G., Ruggenenti P. Rituximab in primary membranous nephropathy: first-line therapy, why not?. Nephron Clin Pract 2014, 128:261-269. 10.1159/000368589.
50. van der Zee J.S., van Swieten P., Aalberse R.C. Inhibition of complement activation by IgG4 antibodies. Clin Exp Immunol 1986, 64:415-422.
51. Hofstra J.M., Debiec H., Short C.D., Pellé T., Kleta R., Mathieson P.W., et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 2012, 23:1735-1743. 10.1681/ASN.2012030242.
52. Hunley T.E., Corzo D., Dudek M., Kishnani P., Amalfitano A., Chen Y.-T., et al. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics 2004, 114:e532-e535. 10.1542/peds.2003-0988-L.
53. Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol 24:198-211. doi:10.1159/000077065.
54. Debiec H., Valayannopoulos V., Boyer O., Nöel L.-H., Callard P., Sarda H., et al. Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy. J Am Soc Nephrol 2014, 25:675-680. 10.1681/ASN.2013030290.
55. Lhotta K., Würzner R., König P. Glomerular deposition of mannose-binding lectin in human glomerulonephritis. Nephrol Dial Transplant 1999, 14:881-886.
56. Augert A., Payré C., de Launoit Y., Gil J., Lambeau G., Bernard D. The M-type receptor PLA2R regulates senescence through the p53 pathway. EMBO Rep 2009, 10:271-277. 10.1038/embor.2008.255.
57. Hoxha E., Thiele I., Zahner G., Panzer U., Harendza S., Stahl R.A.K. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol 2014, 25:1357-1366. 10.1681/ASN.2013040430.
58. Blosser C.D., Ayalon R., Nair R., Thomas C., Beck L.H. Very early recurrence of anti-phospholipase A2 receptor-positive membranous nephropathy after transplantation. Am J Transplant 2012, 12:1637-1642. 10.1111/j.1600-6143.2011.03957.x.
59. Debiec H., Martin L., Jouanneau C., Dautin G., Mesnard L., Rondeau E., et al. Autoantibodies specific for the phospholipase A2 receptor in recurrent and De Novo membranous nephropathy. Am J Transplant 2011, 11:2144-2152. 10.1111/j.1600-6143.2011.03643.x.
60. Larsen C.P., Walker P.D. Phospholipase A2 receptor (PLA2R) staining is useful in the determination of de novo versus recurrent membranous glomerulopathy. Transplantation 2013, 95:1259-1262. 10.1097/TP.0b013e31828a947b.
61. Seitz-Polski B., Payré C., Ambrosetti D., Albano L., Cassuto-Viguier E., Berguignat M., et al. Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients. Nephrol Dial Transplant 2014, 29:2334-2342. 10.1093/ndt/gfu252.
62. Hoxha E., Harendza S., Pinnschmidt H., Panzer U., Stahl R.A.K. PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system. PLoS One 2014, 9:e110681. 10.1371/journal.pone.0110681.
63. Stahl R., Hoxha E., Fechner K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med 2010, 363:496-498. 10.1056/NEJMc1003066.
64. Ruggenenti P., Cravedi P., Sghirlanzoni M.C., Gagliardini E., Conti S., Gaspari F., et al. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol 2008, 3:1652-1659. 10.2215/CJN.01730408.
65. Ruggenenti P., Cravedi P., Remuzzi G. Rituximab for membranous nephropathy and immune disease: less might be enough. Nat Clin Pract Nephrol 2009, 5:76-77. 10.1038/ncpneph1007.
66. Gabardi S., Martin S.T., Roberts K.L., Grafals M. Induction immunosuppressive therapies in renal transplantation. Am J Health Syst Pharm 2011, 68:211-218. 10.2146/ajhp090636.
67. Pepper R., Griffith M., Kirwan C., Levy J., Taube D., Pusey C., et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009, 24:3717-3723. 10.1093/ndt/gfp336.
68. Ferri C., Cacoub P., Mazzaro C., Roccatello D., Scaini P., Sebastiani M., et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011, 11:48-55. 10.1016/j.autrev.2011.07.005.
69. Roccatello D., Sciascia S., Rossi D., Alpa M., Naretto C., Russo A., et al. Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis. Am J Nephrol 2011, 34:175-180. 10.1159/000329535.
70. Howman A., Chapman T.L., Langdon M.M., Ferguson C., Adu D., Feehally J., et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet Lond Engl 2013, 381:744-751. 10.1016/S0140-6736(12)61566-9.
71. Aalberse R.C., Schuurman J. IgG4 breaking the rules. Immunology 2002, 105:9-19.
72. Meka R.R., Venkatesha S.H., Dudics S., Acharya B., Moudgil K.D. IL-27-induced modulation of autoimmunity and its therapeutic potential. Autoimmun Rev 2015, 14:1131-1141. 10.1016/j.autrev.2015.08.001.
73. Dhaeze T., Stinissen P., Liston A., Hellings N. Humoral autoimmunity: a failure of regulatory T cells?. Autoimmun Rev 2015, 14:735-741. 10.1016/j.autrev.2015.04.006.